Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives final approval for Everolimus tablets (generic for ZORTRESS(r)) in the US market22-05-2021
22-05-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment21-05-2021
Alembic, Natco, 3 more firms to make anti-black fungus drug: Centre
Companies have also placed orders for importing 600,000 vials of Amphotericin-B, says Union minister Mansukh Mandaviya20-05-2021
NATCO PHARMA LTD. - 524816 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31, 202120-05-2021
Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib
Drug firm Eli Lilly said it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India17-05-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India17-05-2021
Covid drug: Natco eyes patent waiver
Making its case, Natco's application said Olumiant is not manufactured in India less than 9,000 tablets were imported in 2019 and 2020, at an average cost of Rs 3,230 per tablet. Citing the pricing as a significant barrier, it said a 14-day regimen (one tablet a day) works out to approximately Rs 45,220 per patient, which most Indians can ill-afford.06-05-2021
Natco gets emergency nod for Covid-19 drug 'Baricitinib'
Natco will now request a "compulsory license" based on emergency use and in light of the grave and serious public health emergency across India due to the Covid-19 pandemic03-05-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment03-05-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment03-05-2021